Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.71 |
| ▸ | HTR2A | P28223 | 2/20 | 0.71 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 12/20 | 0.62 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2538131 | 0.98 | TAAR1 (0.68) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Putrescine SCHEMBL27220945 | 0.93 | HTR2A (0.65) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Boric Acid SCHEMBL27782268 | 0.91 | TAAR1 (0.60) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL6532602 | 0.89 | MAOB (0.73) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Acetic Acid SCHEMBL4653250 | 0.88 | FFAR1 (0.58) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Beta-Alanine SCHEMBL27220937 | 0.86 | FFAR1 (0.72) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL416652 | 0.86 | MAOA (0.64) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL1047500 | 0.84 | TAAR1 (0.89) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL8911924 | 0.84 | MAOA (0.75) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Phenethylamine SCHEMBL1331271 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108586579-B | Quasi-peptide, derivative, salt, preparation method and application thereof | 京东方科技集团股份有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-10941180-B2 | Peptoid compound, and derivative, salt, preparation method and use thereof | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2021-03-09 | — | — | US | claimed |
| US-20190345198-A1 | PEPTOID COMPOUND, AND DERIVATIVE, SALT, PREPARATION METHOD AND USE THEREOF | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2019-11-14 | — | — | US | claimed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | ALI MOHAMMED A | 2010-03-04 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| EP-1986996-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | Abiogen Pharma S.p.A. (IT) | 2008-11-05 | — | — | EP | claimed |
| EP-1907004-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | claimed |
| WO-2007088571-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2007-08-09 | — | — | WO | claimed |
| JP-2007500717-A | — | — | 2007-01-18 | — | — | JP | claimed |
| WO-2007005763-A2 | COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2007-01-11 | — | — | WO | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | claimed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | TAAR1 2968/4885HTR2A 2196/4885CYP2A6 1723/4885 |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | TAAR1 2591/4885HTR2A 289/4885CYP2A6 1556/4885 |
| US-10941180-B2 | Peptoid compound, and derivative, salt, preparation method and use thereof | PNMT, VIP, DNPEP | TAAR1 2738/4885HTR2A 1415/4885CYP2A6 4303/4885 |
| US-20190345198-A1 | PEPTOID COMPOUND, AND DERIVATIVE, SALT, PREPARATION METHOD AND USE THEREOF | PNMT, VIP, DNPEP | TAAR1 2738/4885HTR2A 1415/4885CYP2A6 4303/4885 |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | REN, IAPP, ACE | TAAR1 2579/4885HTR2A 3270/4885CYP2A6 859/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | TAAR1 2558/4885HTR2A 2298/4885CYP2A6 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.